Israeli Pharma trade Balance In 1995
Exports of pharmaceuticals and fine chemicals from Israel fell 8% in 1995 to $237 million, says the Israel Manufacturers Association, which adds that this was due to the transfer abroad of some manufacturing activities.
However, says Amir Makov, chairman of the IMA's chemical and pharmaceutical section, last year exports of biotechnology and diagnostic products rose 15.1% to $120 million. Imports of pharmaceuticals, including bulk chemicals, rose 22.5%.
EU R&D Funding Program In 1995, 16 proposals were made to the European Union's R&D Programme by Israeli researchers, mainly from the Weizmann Institute, the University of the Negev in Beersheva, Tel Aviv University and the Technion in Haifa.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze